HER-2/neu overexpression is an independent prognostic factor in colorectal cancer

International Journal of Colorectal Disease

Volumn 22, Issue 5, 2007, Pages 491-497

  Park, Dong I ^a   Kang, Mun Su ^a   Oh, Suk Joong ^a   Kim, Hong Joo ^a   Cho, Yong Kyun ^a   Sohn, Chong I ^a   Jeon, Woo Kyu ^a   Kim, Byung Ik ^a   Han, Won Kon ^a   Kim, Hungdai ^a   Ryu, Seung Ho ^a   Sepulveda, Antonia R ^b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Colonic neoplasms; HER 2 neu

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLON SURGERY; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RECTUM SURGERY; RECURRENCE RISK; SOUTH KOREA; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KOREA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; SURVIVAL RATE;

EID: 33947637653     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-006-0192-8     Document Type: Article

References (40)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics, 2003. CA Cancer J Clin 53:5-26
2. Ministry of Health and Welfare and National Cancer Center. Annual Report of the Korea Central Cancer Registry, 2002
3. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T (1986) The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644-1646
4. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U et al (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139
5. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA (1987) erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178-182
6. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792
7. Kaptain S, Tan LK, Chen B (2001) Her-2/neu and breast cancer. Diagn Mol Pathol 10:139-152
8. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726
9. McKenzie SJ, DeSombre KA, Bast BS, Hollis DR, Whitaker RS, Berchuck A, Boyer CM, Bast RC Jr (1993) Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer 71:3942-3946
10. Hirashima N, Takahashi W, Yoshii S, Yamane T, Ooi A (2001) Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: A comparative immunohistochemical and fluorescence in situ hybridization study. Mod Pathol 14:556-562
11. Ishikawa T, Kobayashi M, Mai M, Suzuki T, Ooi A (1997) Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. Am J Pathol 151:761-768
12. Cohen JA, Weiner DB, More KF, Kokai Y, Williams WV, Maguire HC Jr, LiVolsi VA, Greene MI (1989) Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. Oncogene 4:81-88
13. Caruso ML, Valentini AM (1996) Immunohistochemical p53 overexpression correlated to c-erbB-2 and cathepsin D proteins in colorectal cancer. Anticancer Res 16:3813-3818
14. Osako T, Miyahara M, Uchino S, Inomata M, Kitano S, Kobayashi M (1998) Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology 55:548-555
15. D'Emilia J, Bulovas K, D'Ercole K, Wolf B, Steele G Jr, Summerhayes IC (1989) Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon. Oncogene 4:1233-1239
16. Kay EW, Mulcahy H, Walsh CB, Leader M, O'Donoghue D (1994) Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes' B colorectal carcinoma. Histopathology 25:455-461
17. Yang JL, Ow KT, Russell PJ, Ham JM, Crowe PJ (1996) Higher expression of oncoproteins c-myc, c-erb B-2/neu, PCNA, and p53 in metastasizing colorectal cancer than in nonmetastasizing tumors. Ann Surg Oncol 3:574-579
18. Kapitanovic S, Radosevic S, Kapitanovic M et al (1997) The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 112:1103-1113
19. Bruderlein S, van der Bosch K, Schlag P, Schwab M (1990).Cytogenetics and DNA amplification in colorectal cancers. Genes Chromosomes Cancer 2:63-70
20. Knyazev PG, Imyanitov EN, Chernitca OI, Nikiforova IF, Hanson KP (1992) Amplification of ERBB-2 (HER-2/NEU) oncogene in different neoplasms of patients from USSR. Oncology 49:162-165
21. Gutman M, Ravia Y, Assaf D, Yamamoto T, Rozin R, Shiloh Y (1989) Amplification of c-myc and c-erbB-2 proto-oncogenes in human solid tumors: Frequency and clinical significance. Int J Cancer 44:802-805
22. Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A, Mihatsch MJ, Kallioniemi OP, Sauter G (1999) Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 5:1966-1975
23. Tal M, Wetzler M, Josefberg Z, Deutch A, Gutman M, Assaf D, Kris R, Shiloh Y, Givol D, Schlessinger J (1988) Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues. Cancer Res 48:1517-1520
24. Lazaris AC, Theodoropoulos GE, Anastassopoulos P, Nakopoulou L, Panoussopoulos D, Papadimitriou K (1995) Prognostic significance of p53 and c-erbB-2 immunohistochemical evaluation in colorectal adenocarcinoma. Histol Histopathol 10:661-668
25. Saeki T, Salomon DS, Johnson GR, Gullick WJ, Mandai K, Yamagami K, Moriwaki S, Tanada M, Takashima S, Tahara E (1995) Association of epidermal growth factor-related peptides and type I receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas. Jpn J Clin Oncol 25:240-249
26. Sun XF, Carstensen JM, Stal O, Zhang H, Nordenskjold B (1995) c-erbB-2 oncoprotein in relation to DNA ploidy and prognosis in colorectal adenocarcinoma. APMIS 103:309-315
27. Nathanson DR, Culliford AT 4th, Shia J et al (2003) HER 2/neu expression and gene amplification in colon cancer. Int J Cancer 105:796-802
28. Ochs AM, Wong L, Kakani V et al (2004) Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival. Clin Colorectal Cancer 4:262-267
29. Sobin LH, Wittekind C (eds) (1997) TNM classification of malignant tumors, 5th edn. Wiley-Liss, New York, 227 p
30. Pauletti G, Dandekar S, Rong H et al (2000) Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18:3651-3664
31. Seidal T, Balaton AJ, Battifora H (2001) Interpretation and quantification of immunostains. Am J Surg Pathol 25:1204-1207
32. Pauletti G, Godolphin W, Press MF, Slamon DJ (1996) Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13:63-72
33. Jain S, Filipe MI, Gullick WJ, Linehan J, Morris RW (1991) c-erbB-2 proto-oncogene expression and its relationship to survival in gastric carcinoma: An immunohistochemical study on archival material. Int J Cancer 48:668-671
34. Kameda T, Yasui W, Yoshida K, Tsujino T, Nakayama H, Ito M, Ito H, Tahara E (1990) Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification. Cancer Res 50:8002-8009
35. Kraus MH, Popescu NC, Amsbaugh SC, King CR (1987) Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 6:605-610
36. Hollywood DP, Hurst HC (1993) A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines. EMBO J 12:2369-2375
37. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712
38. Joh JW, Noh DY, Bae CD, Choi KJ, Park JB (1996) Amplification and over-expression of erbB-2 oncogene in primary human breast tumors. Exp Mol Med 28:47-53
39. Kuwada SK, Kuang J, Li X (2005) Integrin alpha 5/beta 1 mediates HER-2 expression in colon cancer cells. J Biol Chem 280:19027-19035
40. Schnitt SJ (2001) Breast cancer in the 21st century: Neu opportunities and neu challenges. Mod Pathol 14:213-218